-
What's Hot On TheStreet
Friday, April 29, 2011 - 2:31pm | 314Here's what Benzinga's reading on our friend, TheStreet.com. What's Hot On TheStreet 5 Worst-Performing S&P 500 Stocks of 2011 TThe S&P 500 Index is rising for the third year in a row, increasing 7% so far in 2011. The best performers are National Semiconductor(NSM), Biogen Idec(BIIB) and...
-
Court Ruling For Embryonic Stem Cells Boost Stocks (STEM, CELG, OSIR)
Friday, April 29, 2011 - 1:09pm | 188A court ruling allowing the federal government to fund embryonic stem cells has boosted some stem cell stocks, and handed a victory to the Obama administration. Last year, a federal judge ruled that the research violated the law because embryos were destroyed, and it put those working with adult...
-
Hearing US Appeals Court Overturns Ban on Stem-Cell Funding (GERN, STEM)
Friday, April 29, 2011 - 11:08am | 30Hearing US Appeals Court Overturns Ban on Stem-Cell Funding, Affecting (NASDAQ: GERN) (NASDAQ: STEM)
-
Dream Stocks: April's Strongest Performers (SIFY, AMRN, REDF, KUTV, ACAD)
Friday, April 29, 2011 - 11:06am | 318The following five stocks have made shareholders extremely happy recently, as they are the top percentage gainers in the market for the month of April. All of the companies reside in the NASDAQ, as pharmaceutical and internet stocks have garnered significant attention from investors and money...
-
J.P. Morgan Neutral On ImmunoGen After Earnings (IMGN)
Friday, April 29, 2011 - 10:56am | 191J.P. Morgan Chase & Co. has a Neutral rating and a $7 price target on shares of ImmunoGen (NASDAQ: IMGN). In a note to investors, J.P. Morgan writes, "IMGN reported relatively in-line FY3Q11 results and offered a pipeline update including progress on its early stage drugs. Our underlying...
-
CEL-SCI Corporation Receives Final Canadian Government Approval to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
Friday, April 29, 2011 - 9:15am | 85CEL-SCI Corporation (NYSE: CVM) announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final “no objection” letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine® in Canada. This final approval was...
-
Avanir Ticks Higher on TheStreet.com Video (AVNR)
Friday, April 29, 2011 - 9:10am | 70Avanir (NASDAQ: AVNR) is ticking over 2% higher this morning after TheStreet.com posted a video about the "next big thing in biotech." Adam Feuerstein, a TheStreet.com columnists, discusses the possible trading ideas for Avanir ahead of Dendreon (NASDAQ: DNDN) earnings release next week.
-
Benzinga's Top Pre-Market NASDAQ Losers (ONTY, RIMM, INFN, CROX)
Friday, April 29, 2011 - 8:22am | 133Oncothyreon Inc (NASDAQ: ONTY) dipped 17.00% to $4.10 in the pre-market session. ONTY priced an underwritten public offering of 10,000,000 shares of its common stock at $4.00 per share. Research In Motion Limited (NASDAQ: RIMM) lost 12.72% to $49.39 in the pre-market session. RIMM cut its Q1...
-
Oncothyreon Prices $40.0 Million Public Offering of Common Stock, 10M Shares Priced at $4 Each, Sees Proceeds of $37.4M (ONTY)
Friday, April 29, 2011 - 8:06am | 114Oncothyreon Inc. (NASDAQ: ONTY) today announced that it has priced an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $4.00 per share for gross proceeds of $40.0 million. The net proceeds from the sale of the shares, after deducting the underwriters...
-
Auriga Assumes Coverage Of UTHR
Friday, April 29, 2011 - 7:49am | 183Auriga has assumed coverage of United Therapeutics Corp. (NASDAQ: UTHR) at a Buy rating and with a price target of $90. According to Auriga, “We are assuming coverage of United Therapeutics (UTHR) with a Buy rating and a $90 price target. UTHR reported 1Q11 revenues that were once again below both...
-
A Peek Into The Market Before The Trading Starts
Friday, April 29, 2011 - 7:34am | 379Pre-open movers US stock futures are slightly higher this morning as investors are awaiting economic reports and corporate results. Futures on the Dow Jones Industrial Average gained 10 points to 12,718.00 and S&P 500 index futures rose 1 point to 1,355.90. Futures on the Nasdaq 100 rose 2.75...
-
J.P. Morgan Maintains Overweight on BioMarin Pharmaceuticals (BMRN)
Friday, April 29, 2011 - 7:32am | 101J.P. Morgan is out with its report today on BioMarin Pharmaceuticals (NASDAQ: BMRN), maintaining Overweight. In a note to clients, J.P. Morgan writes, "After market close, BMRN reported a generally in-line quarter that contained few surprises. Overall, management's update was pretty quiet as the...
-
NeurogesX CEO Anthony DiTonno to Retire by Year End (NGSX)
Friday, April 29, 2011 - 7:02am | 51NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that long time CEO Anthony DiTonno will retire by December 31, 2011. The Board of Directors has initiated a formal executive search for a Chief...
-
FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C (VRTX)
Thursday, April 28, 2011 - 4:22pm | 134Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously to recommend FDA approval of telaprevir for people with genotype 1 chronic hepatitis C. The Committee recommended by a vote of 18...
-
BioMarin Pharma Reports EPS of $0.14 vs. $(0.10) Estimate; Revenues $109.5M vs. $103.8M Estimate (BMRN)
Thursday, April 28, 2011 - 4:17pm | 22BioMarin Pharma (NASDAQ: BMRN) Reports EPS of $0.14 vs. $(0.10) Estimate; Revenues $109.5M vs. $103.8M Estimate